Clinical Trial Update: Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing omalizumab's impact on quality of life and angioedema frequency in patients with chronic spontaneous urticaria refractory to therapy, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema
• Spontaneous Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria, Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2020-09-09